NCT01978249

Brief Summary

Short description for lay public, include brief statement of the study hypothesis

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for not_applicable colorectal-cancer

Timeline
Completed

Started Sep 2013

Geographic Reach
1 country

12 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2013

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 31, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 7, 2013

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2015

Completed
Last Updated

August 14, 2018

Status Verified

August 1, 2018

Enrollment Period

2.2 years

First QC Date

October 31, 2013

Last Update Submit

August 12, 2018

Conditions

Keywords

Colorectal cancerPrimary tumor resectionChemotherapyOverall survivalQuality of life

Outcome Measures

Primary Outcomes (1)

  • Comparison of the overall survival between patients who underwent primary tumor resection and patients who received chemotherapy without primary tumor resection

    Comparison of the overall survival between patients who underwent primary tumor resection followed by chemotherapy and patients who received chemotherapy without primary tumor resection in stage IV colorectal cancer patients with unresectable metastasis.

    2 years after allocation

Secondary Outcomes (1)

  • Analysis of primary tumor related complications in the chemotherapy group and postoperative complications in the primary tumor resection followed by the chemotherapy group.

    2 years after allocation

Other Outcomes (1)

  • To compare the quality of life between the two groups using the Korean version of EORTC QLQ (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire)-C30.

    2 years after allocation

Study Arms (2)

Chemotherapy first without primary tumor resection

EXPERIMENTAL

Patients will receive chemotherapy first without primary tumor resection.

Procedure: Systemic chemotherapy

Primary tumor resection followed by chemotherapy

ACTIVE COMPARATOR

Patients will receive primary tumor resection followed by chemotherapy.

Procedure: primary tumor resection (PTR)

Interventions

Chemotherapy first without primary tumor resection

primary tumor resection (PTR) using open or laparoscopy or robotic surgery

Primary tumor resection followed by chemotherapy

Eligibility Criteria

Age20 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age : between 20 and 90 years old
  • Histologically confirmed adenocarcinoma of the colon or the upper rectum
  • Patients with resectable primary colon or upper rectal cancer and unresectable metastatic lesions.
  • Patients with no primary cancer related symptoms.
  • ECOG performance status of 0 - 2
  • Appropriate organ functions (hepatic transaminases - less than 5 times the normal range; bilirubin - less than 2 times the normal range; creatinine serum - less than 1.5 times the normal range; thrombocyte - more than 100,000/µl; neutrophil - more than 1,500/µl)
  • ASA score of \< 3
  • An informed consent form has been signed by the patient.

You may not qualify if:

  • The patient received adjuvant chemotherapy within the past 6 months.
  • The patient received chemotherapy for metastatic colon cancer.
  • The patient was planning to have curative surgery for the metastatic lesions.
  • The primary cancer is unresectable.
  • Patients with peritoneal carcinomatosis.
  • Patients with mid and low rectal cancer (\< 10cm)
  • Patients with primary tumor related complications such as intestinal obstruction, intractable bleeding, and perforation, that needs to be treated.
  • ASA score of \> 4
  • The patient has chronic hepatitis or cirrhosis. An asymptomatic HBV or HCV carrier can participate.
  • Patients with an active infection, which need antibiotic therapy, during the randomization period.
  • Pregnant or breastfeeding women
  • Patients who were enrolled in another clinical trial during the time of enrollment (within the 28 day randomization period).
  • Patients with another different malignant tumor during the past 5 years. Patients with treated non-melanoma skin cancer or cervical cancer can be enrolled in this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

University Sacred Heart Hospital

Anyang-si, Gyeonggi-do, South Korea

Location

National Cancer Center

Ilsan, Gyeonggi-do, South Korea

Location

Gachon University, Gil Hospital

Incheon, Gyeonggi-do, South Korea

Location

Seoul National University, Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Location

Yeongnam University Hospital

Daegu, Gyeongsang-do, South Korea

Location

Wonkwang University Hospital

Iksan, Jeollabukdo, South Korea

Location

Chonnam National University Hospital

Gwangju, Jeonlla Nam-do, South Korea

Location

Kyungpook National University Hospital

Daegu, South Korea

Location

Department of Surgery, Yonsei University College of Medicine

Seoul, 120-752, South Korea

Location

Asan Medical Center

Seoul, South Korea

Location

Seoul National University Hospital

Seoul, South Korea

Location

Yonsei University, Gangnam Severance Hospital

Seoul, South Korea

Location

Related Publications (1)

  • Kim CW, Baek JH, Choi GS, Yu CS, Kang SB, Park WC, Lee BH, Kim HR, Oh JH, Kim JH, Jeong SY, Ahn JB, Baik SH. The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial. Trials. 2016 Jan 19;17:34. doi: 10.1186/s13063-016-1164-0.

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

Neoadjuvant Therapy

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

Combined Modality TherapyTherapeutics

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 31, 2013

First Posted

November 7, 2013

Study Start

September 1, 2013

Primary Completion

November 1, 2015

Study Completion

November 1, 2015

Last Updated

August 14, 2018

Record last verified: 2018-08

Locations